Table 3

Comparison of baseline parameters in patients with or without a history of SCI

CharacteristicHistory of SCIP
Yes (n = 38)No (n = 151)
Sex, n (%)    
 Male (n = 88) 21 (23.9%) 67 (76.1%) .276 
 Female (n = 101) 17 (16.8%) 84 (83.2%)  
G6PD, n (%)    
 Normal (n = 152) 31 (20.4%) 121 (79.6%)  
 Deficiency (n = 18) 6 (33.3%) 12 (66.7%) .230 
α-thalassemia, n (%)    
 Present (n = 76) 14 (18.4%) 62 (81.6%)  
 Absent (n = 104) 24 (23.1%) 80 (76.9%) .467 
Parameters at baseline, n (mean [SD])    
 White blood cell count, 109/L 37 (15.1 [4.9]) 134 (14.3 [4.8]) NS 
 Neutrophil count, 109/L 34 (6.5 [3.1]) 130 (5.8 [3.2]) NS 
 Platelet count, 109/L 36 (363.2 [147.6]) 133 (350.5[128.0]) NS 
 Hemoglobin level, g/dL 37 (7.8 [1.1]) 134 (8.31 [1.21]) .016* 
 Mean corpuscular volume, fL 35 (80.7 [7.7]) 133 (77.1 [9.5]) .025* 
 Reticulocyte count, 109/L 35 322.4 (105.6) 128 (286.3 [122.8]) NS 
 HbF, % 3 213.1 (6.9) 125 (16.5 [8.5]) .020* 
 SpO2, % 1 497.0 (3.7) 58 (98.0 [2.0]) NS 
 LDH, IU/L 30 863 (414) 100 (776 [351]) NS 
CharacteristicHistory of SCIP
Yes (n = 38)No (n = 151)
Sex, n (%)    
 Male (n = 88) 21 (23.9%) 67 (76.1%) .276 
 Female (n = 101) 17 (16.8%) 84 (83.2%)  
G6PD, n (%)    
 Normal (n = 152) 31 (20.4%) 121 (79.6%)  
 Deficiency (n = 18) 6 (33.3%) 12 (66.7%) .230 
α-thalassemia, n (%)    
 Present (n = 76) 14 (18.4%) 62 (81.6%)  
 Absent (n = 104) 24 (23.1%) 80 (76.9%) .467 
Parameters at baseline, n (mean [SD])    
 White blood cell count, 109/L 37 (15.1 [4.9]) 134 (14.3 [4.8]) NS 
 Neutrophil count, 109/L 34 (6.5 [3.1]) 130 (5.8 [3.2]) NS 
 Platelet count, 109/L 36 (363.2 [147.6]) 133 (350.5[128.0]) NS 
 Hemoglobin level, g/dL 37 (7.8 [1.1]) 134 (8.31 [1.21]) .016* 
 Mean corpuscular volume, fL 35 (80.7 [7.7]) 133 (77.1 [9.5]) .025* 
 Reticulocyte count, 109/L 35 322.4 (105.6) 128 (286.3 [122.8]) NS 
 HbF, % 3 213.1 (6.9) 125 (16.5 [8.5]) .020* 
 SpO2, % 1 497.0 (3.7) 58 (98.0 [2.0]) NS 
 LDH, IU/L 30 863 (414) 100 (776 [351]) NS 

Biological parameters were recorded before age 3 years. NS, not significant.

*

Significant tests.

Close Modal

or Create an Account

Close Modal
Close Modal